Get started

LLY

Eli Lilly's Stock Surges 4.77% on Weight-Loss Wonder DrugEli Lilly & Company (NYSE: NYSE:LLY ) has sent shockwaves through the pharmaceutical industry with the meteoric success of its weight-loss drug Zepbound, propelling the company's stock to new heights despite a mixed first-quarter performance. With sales of Zepbound surpassing Wall Street's projections by a staggering margin, Eli Lilly has raised its sales outlook for the year, overshadowing slight revenue dips from other key products. Zepbound's Triumph and Guidance Boost: In a remarkable turn of events, Zepbound emerged as the star performer in Eli Lilly's ( NYSE:LLY ) portfolio, surpassing sales forecasts by a substantial margin. With first-quarter sales reaching $517.4 million, well above the expected $373 million, Zepbound's success has prompted Eli Lilly to raise its sales guidance for the year by a staggering $2 billion. This unexpected surge in demand for the weight-loss drug has underscored Eli Lilly's position as a frontrunner in the pharmaceutical industry and has reignited investor confidence in the company's growth prospects. Challenges and Opportunities in the Diabetes Market: While Zepbound's success has captured headlines, Eli Lilly ( NYSE:LLY ) faces challenges in its diabetes portfolio, particularly with drugs like Mounjaro and Trulicity. Despite a surge in sales for Mounjaro, both drugs fell short of analyst expectations, highlighting the competitive landscape in the diabetes market. However, with plans to expand production significantly in the second half of the year, Eli Lilly remains optimistic about its ability to meet the growing demand for diabetes treatments and capitalize on emerging opportunities in the market. Analyst Insights and Market Response: Analysts have offered mixed assessments of Eli Lilly's performance, with some highlighting the company's robust guidance raise and the continued strength of Zepbound, while others have raised concerns about softer sales in the GLP-1 franchise. However, overall sentiment remains positive, with analysts reaffirming their bullish outlook on Eli Lilly's stock and emphasizing the company's strategic initiatives to drive growth and innovation. Looking Ahead: As Eli Lilly ( NYSE:LLY ) charts its course forward, all eyes are on the continued success of Zepbound and the company's ability to navigate challenges in the diabetes market. With a bolstered sales outlook and a commitment to expanding production capacity, Eli Lilly ( NYSE:LLY ) is poised to capitalize on evolving consumer preferences and emerging opportunities in the pharmaceutical landscape.
NYSE:LLYLong
by DEXWireNews
LLY, LILLY IS THIS STOCK PRICE SILLY?I hope you appreciated my rhyme. So what to say about this. One main trend line at the moment. Big support incoming at 580 to 560 range. Really big support at 108. The lines in the middle (light green and red) are fairly weak and more likely short term targets. I assume the long term targets will line up well with the gaps which are marked in orange. Orange also on RSI, which is saying be careful. Short term can take it up to 980 or so but I think the lower targets are more likely and we'll see the higher targets after trend breaks and before it starts to really drop. However, there are a lot of possibilities that can occur. The main possibility looks to be a chance of a move to 980, but more likely won't get there and might stick around 780. I really have a hard time saying what this will do and when it will top out, I could tell you more if I watched this daily, but I don't. This chart is long term price targets for the downside and the upside. Given the single trend, you'll need a new chart as more develop, feel free to message if I haven't updated after some time. I think that covers most everything. Summary. I think this stock is overvalued big time, but still has potential to keep seeing more upside in the short and mid term.
NYSE:LLY
by nicktussing77
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA approved drugs into the market. It has but out a series of favorable earnings reports with optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume pumps and just keeps grinding higher. This is because it is in the shadows of big technology stocks. Revenues consistently beat analysts' forecasts quarter after quarter. Institutions add small lots trying to preserve the price for future buys without any run-ups. I have done the same thing and I will continue to do so. While day trading biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are parked for growth and compounding.
NYSE:LLYLong
by AwesomeAvani
1
ELI LILLY Is a -20% correction possible?Eli Lilly (LLY) gave us the best possible buy entry at the bottom of the Channel Up last time we gave a call on it (December 14 2023, see chart below) and not hit our $705.00 Target but also aggressively broke above the pattern: In order to grasp the magnitude of that move, this time we zoom out on the 1W time-frame where we see the long-term pattern since LLY's parabolic move started, in mid 2018 following 3 years of consolidation. The pattern that emerged since is a 6-year logarithmic Channel Up, which since 2023 has gone extremely parabolic. The key characteristic on this long-term price action is the unique pattern that the 1W MACD forms, a Bearish Cross followed by a Bullish Cross. Four such occurrences since 2018 have caused the stock to form a Higher High top at a minimum 2 weeks and maximum 10 weeks after the Bullish Cross. Currently we are on the 3rd week since the latest 1W MACD Bullish Cross and if it extends to 10 weeks, we can technically expect the new top by April 08 2024. However, the 1st red 1W candle following the Bullish Cross on those 4 past occurrences has always been the top, or near it. Given the fact that LLY is so close to the top of the 6-year Channel Up, we can expect that a correction will start soon. The minimum correction has been -17.44% and the maximum -23.23% (2 occasions out of the 4). Also before a new long-term rally started, the price hit the 1W MA50 (blue trend-line). Long-term investors can wait for such a contact before buying again heavily Eli Lilly for a new 12-month run. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Eli Lilly Stock Soars on Robust Fourth-Quarter PerformanceEli Lilly (NYSE: NYSE:LLY ) has once again defied expectations, propelling its stock to new heights with a stellar fourth-quarter performance that surpassed even the most optimistic forecasts. The pharmaceutical giant's earnings report, released early Tuesday, showcased a remarkable surge in both revenue and adjusted earnings, fueled by the successful launch of its groundbreaking weight loss drug, Zepbound, and buoyed by robust sales of its flagship diabetes treatment, Mounjaro. Earnings Review Earnings figures reveal a standout quarter for Eli Lilly (NYSE: NYSE:LLY ), with adjusted profit soaring to $2.49 per share, significantly outpacing the consensus estimate of $2.30 per share among analysts surveyed by FactSet. This remarkable feat represents a substantial increase from the year-earlier period, where earnings stood at $2.09 per share, underscoring the company's impressive growth trajectory. Revenue Result Similarly, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter revenue surged to $9.35 billion, marking a notable 28% increase from the same period last year and surpassing analysts' expectations of $8.95 billion. This remarkable revenue surge can largely be attributed to the stellar performance of Zepbound, the company's newly approved weight loss drug, which generated a staggering $175.8 million in sales during its inaugural quarter on the market. Analysts Views The success of Zepbound has exceeded even the loftiest projections, with analysts predicting the potential for over a billion dollars in sales within its first year alone, positioning it as a potential game-changer in the pharmaceutical industry. Moreover, with its groundbreaking mechanism of action and promising efficacy profile, Zepbound holds the potential to become one of the most significant drugs in Eli Lilly's (NYSE: NYSE:LLY ) portfolio and a major revenue driver in the years to come. The Mounjaro Meanwhile, the continued strong performance of Mounjaro, Eli Lilly's (NYSE: NYSE:LLY ) blockbuster diabetes treatment, further bolstered the company's financials, with fourth-quarter sales soaring to $2.21 billion, far surpassing analysts' expectations. This remarkable growth can be attributed to both increased demand and higher realized prices, underscoring the enduring strength of Eli Lilly's (NYSE: NYSE:LLY ) diabetes franchise. Challenges However, amidst the impressive financial results, Eli Lilly (NYSE: NYSE:LLY ) also faces challenges, notably in its diabetes portfolio, where lower prices for Trulicity and Humalog offset some of the gains from Mounjaro. Despite this setback, the company remains optimistic about its long-term prospects, buoyed by the continued success of its key products and a robust pipeline of innovative therapies. Future Outlook Looking ahead, Eli Lilly (NYSE: NYSE:LLY ) has provided a bullish outlook for the full year, with projected adjusted earnings in the range of $12.20 to $12.70 per share and revenue expected to reach $40.4 billion to $41.6 billion. These optimistic forecasts reflect the company's confidence in its ability to sustain its growth momentum and capitalize on emerging opportunities in the evolving healthcare landscape. Conclusion In conclusion, Eli Lilly's (NYSE: NYSE:LLY ) fourth-quarter performance stands as a testament to its resilience, innovation, and unwavering commitment to advancing patient care. With its groundbreaking therapies and strong financial performance, Eli Lilly (NYSE: NYSE:LLY ) is well-positioned to deliver sustained value to its shareholders while continuing to make a meaningful impact on global healthcare. As Eli Lilly (NYSE: NYSE:LLY ) prepares to engage with investors during its earnings call, all eyes will be on the company as it provides insights into its strategic priorities, pipeline progress, and plans for driving future growth. Amidst a backdrop of rapid innovation and evolving market dynamics, Eli Lilly's (NYSE: NYSE:LLY ) continued success underscores its status as a powerhouse in the pharmaceutical industry and a beacon of hope for patients worldwide.
NYSE:LLYLong
by DEXWireNews
The Healthcare Sector Index $XLV - Worth Watching SPDR Select Sector Fund – Healthcare Index AMEX:XLV The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels. Below I outline some reasons why the healthcare sector is worth paying attention too. The healthcare industry is worth $808 billion in the United States as of 2021. 65% of the industry’s revenue comes from patient care. The global healthcare industry is worth $12 trillion. In the U.S National health expenditures are projected to grow 5.4 percent, on average, over the course of 2023–31 and to account for roughly 20 percent of the economy by the end of that period. The insured share of the population is anticipated to exceed 92 percent through 2023 (figures pending), in part as a result of record-high Medicaid enrolment, and then decline toward 90 percent as coverage requirements related to the COVID-19 public health emergency expire. The growth of the health-care sector is evident in employment data as well. In 1990, about 8 million Americans worked in health care; that figure has since doubled to 16 million. That’s the largest single employment segment in our economy. In addition to the above, the west in general is an aging populace that is living longer. We will need these services more than we need staples during a recession. I believe this index can help us gauge the healthcare sector and what direction it will go next. We can watch the levels outlines and make a play if we wish. We have a hard upper boundary and lower boundary on a parallel channel on the chart. You know what to do when we breach any of these levels. Outlined on the chart XLV fund provides exposure to companies in pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. XLV is the oldest in the segment, as such it is used widely for strategic or tactical positions. Since XLV is both cap weighted and fishes only from the S&P 500, it tilts heavily toward mega-caps. For focused exposure to leading health care names, XLV is tough to beat. Top Five Holdings UnitedHealth Group Inc NYSE:UNH 9.63% Eli Lilly and Co NYSE:LLY 9.19% Johnson & Johnson NYSE:JNJ 7.46% Merck & Co NYSE:MRK 5.46% AbbVie Inc 5.41% Stay Healthy and Nimble Folks PUKA
AMEX:XLV
by PukaCharts
Updated Swing Trading Watchlist - Pullback OpportunitiesHello Traders, As we dive deeper into our trading strategy inspired by Mark Minervini, I'm excited to share a detailed analysis of our updated watchlist: www.tradingview.com This list is meticulously curated, focusing on stocks poised for potential pullback entries, suitable for short to medium-term trades. Here’s what we’ve analyzed: Selection of Stocks in Strong Uptrends: Our primary filter is selecting stocks exhibiting strong uptrends over the past weeks or months. We use specific criteria like stocks trading above their 50-day and 200-day moving averages, a sign of enduring strength. Additionally, we look for stocks outperforming the market index, indicating relative strength. Volume Analysis During Pullbacks: We observe the trading volume during pullbacks. An ideal scenario is a pullback on lower-than-average volume, suggesting a lack of selling pressure. A sudden increase in volume can sometimes signal capitulation, which might lead to a potential reversal. Key Support Levels and Technical Indicators: Stocks approaching critical support levels, such as major moving averages or historical support zones, are of high interest. We combine this with technical indicators like the RSI (Relative Strength Index) and MACD (Moving Average Convergence Divergence) to gauge oversold conditions and potential bullish divergence. Price Action and Chart Patterns: We're scrutinizing price patterns that align with Minervini's SEPA (Specific Entry Point Analysis) criteria. This includes looking for stocks forming bases, tight consolidations, or exhibiting orderly pullbacks without significant volume spikes. Flags, pennants, and narrow range days near support areas are particularly noteworthy. Sector and Market Sentiment Analysis: Understanding the current market sentiment and sector rotation plays a crucial role. Stocks in leading sectors or those showing resilience in a weak market are preferred. We also consider the broader market trend and economic indicators to assess the overall risk environment. Risk Management and Entry Points: Each stock on our watchlist comes with a predefined risk management plan, including stop-loss levels and potential entry points. We're waiting for a reversal signal, such as a high-volume rebound off a support level or a break of a short-term downtrend line, to initiate positions. Earnings and Fundamental Check: While our focus is on technical analysis, we don't ignore fundamental aspects. We check upcoming earnings dates and ensure that the stocks have solid fundamentals, aligning with Minervini's preference for quality stocks. Conclusion : This watchlist represents a blend of technical prowess and strategic foresight, aiming to capitalize on pullback opportunities in strong stocks. Remember, the key to successful swing trading lies in timing, precision, and risk management. Stay alert for real-time updates as these setups evolve. Let's capture the market's rhythm together!
NASDAQ:ADBE
by JS_TechTrading
ELI LILLY targeting $705.00 if the 1D MA100 holds.Eli Lilly (LLY) has been on an incredible run ever since our March 01 buy signal (see chart below) that even broke above Channel Up: We have been strong supporters of the company's fundamentals and those are translated into strong technical bullish patters, offering solid buy opportunities. Another such opportunity exists now as the price is trading around the 1D MA50 (blue trend-line) near the bottom of the 2023 Channel Up. As long as the 1D MA100 (green trend-line), which is exactly on the Channel's bottom, holds, we remain bullish, targeting the 2.382 Fibonacci extension (similar to the May 22 High) at $705.00. If the 1D MA100 breaks though, we will take the loss and sell instead targeting the 1D MA200 (orange trend-line) at $500.00 where a stronger buy opportunity exists. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
ELI LILLY Expected to rally above 700 if these conditions hold.LLY is holding the 1D MA50 on a neutral 1D technical outlook (RSI = 47.021, MACD = 2.060, ADX = 24.740), which indicates a strong demand level for the stock. The 1D RSI which is under a LH trendline shows that the stock price is at a pre bullish breakout accumulation like the last week of July and early August. If it holds the line, we will buy and aim a +30% rise (TP = 710.00), following a regression of -8% on each top. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope
1
ELI LILLY Our gem on the verge of making a paradigm shift.Eli Lilly and Company (LLY) has long been one of our best investments a real gem that even withstood and was practically unaffected by the 2022 inflation crisis. For long we have been using the Fibonacci Channel to display LLY's parabolic nature having broken above the 2.0 Fibonacci extension last May. This time the price reversed much quicker than technically expected and is attempting again to break the top (Higher Lows trend-line) of the Channel Up that started in 2020. If it closes above it, then we wil target the 3.0 Fibonacci Channel extension at $700. If it gets rejected and stays within the Channel Up, we will sell and target the recent Support at $520. Note that a break above this 3-year Channel Up may constitute a paradigm shift as the stock has never hit a new upper Fibonacci level that quickly (remember it broke above the 2.0 Fib just 5 months ago). This can transcend LLY into an even more aggressive bullish nature that we can't yet quantify. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
1
ELI LILLY Needs to correct a little more. Massive buy after.Eli Lilly has completed 3 red weeks in a row. The parabolic rise it is seeing for years is seen accurately on this Fibonacci Channel. Every such price peak, pulled back to under the MA100 (1d), which is now at 492.43, in order to gather buyers. Trading Plan: 1. Sell on the current market price. Targets: 1. 490 (between the MA100 (1d) and the Fibonacci 2.0 level. Tips: 1. The MACD (1d) is just formed a Sell Cross. Only once since 2018 has a Sell Cross failed to deliver a sizeable drop. Please like, follow and comment!!
NYSE:LLYShort
by TradingBrokersView
1
ELI LILLY: Possible to start a strong multi week correction.Eli Lilly has seen enormous growth over the past few years and in particularly in 2023. This Channel Up on the log chart's 1W timeframe is the best depiction of the long term trend. The 1W outlook got extremely overbought technically three weeks ago (RSI = 68.989, MACD = 46.590, ADX = 60.019) and is now correcting. The rejection took place at the top of the Channel Up. This is a hint that investors should be exiting LLY and not entering. Historically the most efficient level to buy is on the 1W MA50 with a max extension to the 1W MA100. That is our entry strategy. Don't take chances and take the best possible entry. This stock will reward us enormously in 2024. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYShort
by InvestingScope
4
LLY, This ALL-TIME-HIGH ROCKET is a NEVER ENDING STORY!Hello There! Welcome to my new analysis about LLY on several timeframe perspectives. LLY printed an major bullish breakout literally over night bouncing out of the range. In the recent times the pharma industry transformed into a eager bullish environment since the gains seen because of the "pandemic" and LLY is a stock already present since 1978 in the 19th century, a time before the great depression. The FED is considering a more dovish policy as inflationary pressures in the U.S. decreased and LLY showed an development typical for more bullish stocks within the market, it already bounced before the U.S. CPI release signaled an easing in inflation, such moves are always important to anticipate as it is the case with LLY and the long direction. Within the chart LLY is now forming a flag-formation on the local term which is likely to complete with a breakout in the near future setting up the next wave C extension into the upper directions. On the global term LLY bounced several times within the ascending trendline and has an underlying strong volatility-spike structure which is bolstering the bullish sentiment here. Once LLY has shown up with the breakout dynamics and reached the targets of the local formation this is likely to convert into the continuation of the global trend as well. Currently, the bullish scenario should be considered if the FED does not become more hawkish on interest rates or there is a major demand shortage increasing supply within the pharma market this should be a considerable scenario for the next times. In this manner, thank you everybody for watching, support is greatly appreciated, all the best! VP
NYSE:LLY
by VincePrince
4
ELI LILLY Hit the top of the 4-year Channel. Relief sell-off?Earlier this year we gave a strong buy signal on Eli Lilly and Company (LLY) on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price has now hit (last week) the top of the 4 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame reaching 84.30, breaking above the August 16 2021 High. As last week's 1W candle closed in red (the first after 5 straight bullish weeks) this is considered so far a Higher Highs rejection and calls for an early sell signals towards the end of October, targeting the 1D MA100 (red trend-line) at $500.00, where the stock will start turning into a buy opportunity again (assuming the RSI is below 55.00). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYShort
by TradingShot
ELI LILLY Approaching the top of the Channel. Sell opportunity.Last time we looked at Eli Lilly and Company (LLY) was on March 01 (see chart below) where we called for the most optimal buy entry exactly at the bottom of the bullish pattern: The price is now approaching the top of the 3 year logarithmic Channel Up, highly overbought with the RSI on the 1W time-frame at 80.00. This gradually calls for a sell towards the end of August, targeting the 1D MA100 (red trend-line) at $480.00, where the stock will turn into a buy opportunity again. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYShort
by TradingShot
1
LLY Earnings Play LONG ( Flat Bottom Triangle Breakout)My analysis is on the 2H. I am uniquely qualified in my fundamental analysis. This is a one day until earnings. My thesis is the earnings will stimulate what will be a breakout from a flat bottom triangle. I will buy one share of stock. I will spend a similar amount on call options striking $460 expiring August 11th. I see LLY as surging while PFE is a bit challenged with the fall off in Covid vaccine work. If you find this idea interesting and might appreciate my ideas as to a stop loss and targets, leave a comment. Like and subscribe. Trade well !
NYSE:LLYLong
by AwesomeAvani
1